To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
8 Current news of Alcon
rss
Novartis increases growth potential through integration of Alcon
Novartis growth in new product portfolio and productivity to enable company to absorb the impact of patent losses and maintain robust margins
09-15-2011
Novartis presented an update on its long-term strategy, performance and vision for continued sustainable growth and gave an in-depth overview on the unique position and business model of the new Alcon Division. The company's diversified healthcare portfolio across high growth segments in ...
Novartis completes merger with Alcon
Merger of Alcon into Novartis completed following entry in commercial registry
04-12-2011
Novartis announced that it completed the merger of Alcon, Inc. into Novartis. The completion of the merger follows the Novartis shareholders' approval of the merger, as well as the proposed capital increase at the company's Extraordinary Shareholder Meeting today and the subsequent entry of ...
Novartis merges with Alcon
Novartis Board of Directors unanimously approves merger for a value of USD 168 per Alcon share totaling USD 12.9 billion, comprising share consideration of up to 2.8 Novartis shares and a contingent cash payment
12-21-2010
Novartis announced that it has entered into a definitive agreement with Alcon, Inc. to merge Alcon into Novartis for Novartis shares and a Contingent Value Amount (CVA). Under the terms of the agreement, the merger consideration will include up to 2.8 Novartis shares and a CVA to be settled ...
Novartis completes 77% majority ownership of Alcon adding new growth platform in eye care to its leading healthcare portfolio
08-30-2010
Novartis announced that it has completed its purchase of Alcon stock from Nestlé resulting in 77% ownership of Alcon. This has been achieved by completing the acquisition of the remaining 52% of Alcon shares owned by Nestlé for a total of USD 28.3 billion. Alcon strategically complements ...
Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
10-26-2009
Potentia Pharmaceuticals announced that it has entered into licensing and purchase option agreements with Alcon Research, Ltd., a wholly-owned subsidiary of Alcon, Inc.. The agreements provide Alcon with a license to develop Potentia's leading drug candidate, POT-4, for the treatment of AMD. ...
Alcon to Acquire Swiss Biotechnology Firm, ESBATech AG
ESBATech shareholders retain rights to non-ophthalmic technology and products
09-15-2009
Alcon announced that it has entered into a definitive agreement to acquire ESBATech AG. Alcon will pay ESBATech shareholders $150 million in cash at closing, plus contingent payments of up to $439 million based upon the achievement of future research and development milestones that would be ...
Novartis completes acquisition of 25% stake in Alcon from Nestlé for approximately US$ 10.4 billion in cash
First step toward majority ownership of the world leader in eye care
07-09-2008
Novartis has acquired a 25% stake in Alcon Inc. as part of a definitive agreement with Nestlé S.A. reached in April 2008 that provides the right to acquire majority ownership of the world leader in eye care in two steps. The first step was completed on July 7 when Novartis purchased the ...
Alcon and Amgen Sign Collaboration Agreement to Develop and Commercialize Innovative Therapies in Ophthalmology
04-27-2006
Alcon, Inc. and Amgen announced a broad, multi-target collaboration to jointly research, develop, and commercialize therapeutics for the treatment of eye diseases. The agreement encompasses multiple biological targets and disease areas within the field of ophthalmology. Under the terms of ...
Page 1 From 1
